Progress of chimeric antigen receptor T cells in treatment of B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 74-77, 2021.
Article
en Zh
| WPRIM
| ID: wpr-882243
Biblioteca responsable:
WPRO
ABSTRACT
B-cell lymphoma (BCL) is a highly heterogeneous malignant tumor. In recent years, although the remission rate of BCL patients has been improved with the improvement of diagnosis and treatment methods, some patients still relapse and become refractory. Chimeric antigen receptor T cells (CAR-T) is a novel therapy. At present, CD19 CAR-T has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma. At the 62nd American Society of Hematology Annual Meeting, a number of studies reported the latest progress of CAR-T in the treatment of relapsed/refractory BCL.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2021
Tipo del documento:
Article